Ardelyx, Inc. (ARDX) vs Pacific Biosciences of California, Inc. (PACB)

A side-by-side comparison of Ardelyx, Inc. and Pacific Biosciences of California, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ARDX vs PACB

growth of $100 · dividends reinvested · last 10y
ARDX +4.6% (+0.5%/yr)PACB -68.1% (-10.8%/yr)ARDX compounded faster over this window
0200400600Start $10020182020202220242026$105$32
ARDX PACB

ARDX vs PACB: by the numbers

  • •PACB is the larger company ($840M vs $810M market cap).
  • •Both run net losses; ARDX's is the smaller (-12.35% vs -82.49% net margin).
  • •ARDX grew revenue faster over the past five years (105.14% vs 8.52% CAGR).

Metrics side by side

Valuation

MetricARDXPACB
P/S ratio1.805.28
P/B ratio5.44N/A

Profitability

MetricARDXPACB
Gross margin93.96%35.97%
Operating margin-7.86%-348.46%
Net margin-12.35%-82.49%
ROE-37.38%N/A
ROIC-7.99%-23.80%

Growth (annualized)

MetricARDXPACB
Revenue CAGR (5Y)105.14%8.52%
Total return CAGR (5Y)20.95%-35.20%

Frequently asked

Which has grown faster, ARDX or PACB?
Over the past five years, ARDX grew revenue faster — ARDX at a 105.14% CAGR versus PACB at 8.52%.
How have ARDX and PACB total returns compared?
Over the past 10 years, ARDX delivered -0.20% and PACB delivered -10.80% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.